We discussed a phase II study on LEN/AZa or treatment relapse after  transplantation.   Presenter:Prof Spyridonidis Participants:Dr Liga,Dr Spyridis, Dr Fragopanagou, Dr Verigou

We discussed a case of a young AML patient with  PTPN11 mutated (Glu76Lys, missense, NPM1 neg/ flt3 ITD neg) In a study (Hou et al, Leukemia volume 22, pages 1075–1078 (2008)  (https://doi.org/10.1182/blood-2018-99-110319) PTPN11 mutations were found in 5.1% adult AML patients and they were exclusively missense...

According to bibliography, G-CSF administration on day -1, 8 or during febrile neutropenia is not relevant with the progression of the disease. In contrast, G-CSF administration reduces TRM and can accelerate ANC recovery. As a result, we decided to administer G-CSF from day 15 (from the...

We presented a retospective analysis of BEAM vs BuCYVP16 in HL. BEAM conditioning before AHSCT resulted in a statistically significant  improved PFS and OS and lower relapse when compared with BUCYVP16.  Patients with shorter remission time from diagnosis and in non-CR at  time of AHSCT benefited most from...

When, Where, and How to use FLT3 inhibitors? What is their value? What are the open questions. Presenter:Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

We discussed an excellent review on mechanisms of relapse and its  treatment. - Major mechanisms of relapse include HLA loss, HLA down-regulation, and  expression of coinhibitory ligands. - Combination of donor lymphocyte infusion with immunomodulating agents and tyrosine kinase inhibitors may enhance the graft-versus-leukemia (GVL) effect. - Immune checkpoint inhibitors can induce a...

Στα πλαίσια ενημέρωσης, την Τρίτη 9/4/2019 πραγματοποιήθηκε, στην αίθουσα σεμιναρίων της Παθολογικής κλινικής, παρουσίαση του φαρμακου Cresemba από εκπροσώπους της εταιρείας Pfizer.    

We discussed current concepts and treatment of HCV. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

We discussed a case for BL/BLL which was referred for HSCT. We reviewed the literature regarding BL/ BLL/ DLBCL. In the 2008 revisions to the WHO classification, atypical BL/BLL is no longer formally recognized; many of these cases are now classified as BL, whereas others are...

We presented a case of an isolated myeloid sarcoma and discussed the  current literature with the specific question of transplant or not. Presenter:Prof Spyridonidis Participants:Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

Presenter:Prof Spyridonidis Participants:Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

We discussed a case of conjuctival MALT lymphoma and reviewed the  current literature.   Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

Presenter:Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

Presenter:Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

We discussed 2 interesting papers for mechanisms of relapse post allogeneic HSCT which can be either HLA-loss, HLA-down regulation or immune escape. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

An update on CMV was presented. We discussed the open access slides of the ECIL 7 consensus on CMV. In addition we discussed the recently change of the LAb which performs CMV monitoring and the new reporting (from copies/ml to IU/ml). We discussed...